Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00528970
Registration number
NCT00528970
Ethics application status
Date submitted
11/09/2007
Date registered
14/09/2007
Date last updated
4/09/2019
Titles & IDs
Public title
A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair
Query!
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Post Operative Ileus After Ventral Hernia Repair
Query!
Secondary ID [1]
0
0
3200L2-301
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ileus
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - MOA-728
Treatment: Drugs - Placebo
Experimental: MOA-728 12 mg - Participants will receive methylnaltrexone (MOA-728) 12 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
Experimental: MOA-728 24 mg - Participants will receive MOA-728 24 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
Placebo Comparator: Placebo - Participants will receive placebo matching to MOA-728 as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
Treatment: Drugs: MOA-728
MOA-728 will be administered per the dose and schedule specified in the arm.
Treatment: Drugs: Placebo
Placebo matching to MOA-728 will be administered per the schedule specified in the arm.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Time to First Bowel Movement
Query!
Assessment method [1]
0
0
Time to first bowel movement was measured from the end of surgery (defined as the time when the last skin suture or staple was placed in the participant). Time of the first bowel movement was recorded on the electronic case report form (eCRF). The first bowel movement was defined as a normal stool for a postoperative participant based on the clinical judgment of the investigator or designee. Analysis was performed by Kaplan-Meier estimate. Participants who had a bowel movement but were readmitted to the hospital within 1 week after discharge with a diagnosis of postoperative ileus (POI) were considered censored at the time of the first bowel movement as if the bowel movement had not occurred.
Query!
Timepoint [1]
0
0
Day 1 (From the time of end of surgery [that is; from the first dose of study drug administration]) up to Day 10
Query!
Secondary outcome [1]
0
0
Time to Discharge Eligibility
Query!
Assessment method [1]
0
0
Time to discharge eligibility was measured from the end of surgery (defined as the time when the last skin suture or staple was placed in the participant). Discharge eligibility was defined as tolerance of oral intake of liquids greater than (>) 500 milliliters (mL) per 8 hours without nausea or retching/vomiting. Analysis was performed by Kaplan-Meier estimate.
Query!
Timepoint [1]
0
0
Day 1 (From the time of end of surgery [that is; from the first dose of study drug administration]) up to Day 10
Query!
Secondary outcome [2]
0
0
Time to Discharge Order Written From the End of Surgery
Query!
Assessment method [2]
0
0
The investigator or designee recorded the time of the order. Participants re-admitted to the hospital with a diagnosis of POI within 7 days after discharge was considered treatment failures. Analysis was performed by Kaplan-Meier estimate.
Query!
Timepoint [2]
0
0
Day 1 (From the time of end of surgery [that is; from the first dose of study drug administration]) up to Day 10
Query!
Secondary outcome [3]
0
0
Number of Participants With Clinically Meaningful Events (CMEs) for Nausea or Retching/Vomiting at Day 2 (24 Hours) as Evaluated by the Opioid-Related Symptom Distress Scale (SDS)
Query!
Assessment method [3]
0
0
CMEs were defined using opioid-related SDS (assessed participant-reported levels of severity concerning 10 symptoms associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion and retching/vomiting). CME = any symptom rated as severe (3) or very severe (4), with the exception of confusion. A total CME score was calculated by summing the number of CMEs across symptoms and ranged from 0 to 9. CME was counted for either nausea or vomiting/retching, or both and reported in this outcome measure.
Query!
Timepoint [3]
0
0
Day 2
Query!
Eligibility
Key inclusion criteria
- Males and females, ages 18 and older.
- Scheduled for ventral wall hernia repair with general anesthesia.
- Meets the American Society of Anesthesiologists physical status I, II, or III.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Received investigational drug or procedure within 30 days of randomization.
- Women who are pregnant or lactating.
- Calculated creatinine clearance (Cockcroft-Gault glomerular filtration rate [GFR]
formula) less than or equal to (</=) 50 milliliters/minute (mL/min).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
17/10/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
5/02/2008
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
374
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Adelaide SA
Query!
Recruitment hospital [2]
0
0
- Elizabeth Vale SA
Query!
Recruitment postcode(s) [1]
0
0
5006 - Adelaide SA
Query!
Recruitment postcode(s) [2]
0
0
5112 - Elizabeth Vale SA
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Iowa
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Mississippi
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Missouri
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Nebraska
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New Jersey
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Mexico
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
North Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Ohio
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oklahoma
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oregon
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Rhode Island
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
South Dakota
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Tennessee
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Texas
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Virginia
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Washington
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
West Virginia
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Wisconsin
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Edegem
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Gent Belgium
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Alberta
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
British Columbia
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Quebec
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Berlin
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Muenchen
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Heidelberg
Query!
Country [39]
0
0
Hungary
Query!
State/province [39]
0
0
Nyiregyhaza
Query!
Country [40]
0
0
Hungary
Query!
State/province [40]
0
0
Pecs
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Szekesfehervar
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Veszprem
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Ferrara
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Rome
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Via Giustiniani 2
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Bergamo
Query!
Country [47]
0
0
Korea, Republic of
Query!
State/province [47]
0
0
Seoul
Query!
Country [48]
0
0
Netherlands
Query!
State/province [48]
0
0
Amsterdam
Query!
Country [49]
0
0
Netherlands
Query!
State/province [49]
0
0
Roosendaal
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Lodz
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Szczecin
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Bydgoszcz
Query!
Country [53]
0
0
South Africa
Query!
State/province [53]
0
0
Natal
Query!
Country [54]
0
0
South Africa
Query!
State/province [54]
0
0
Western Cape
Query!
Country [55]
0
0
South Africa
Query!
State/province [55]
0
0
Moreletapark Pretoria
Query!
Country [56]
0
0
South Africa
Query!
State/province [56]
0
0
Pretoria Gauteng
Query!
Country [57]
0
0
South Africa
Query!
State/province [57]
0
0
Pretoria
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Bausch Health Americas, Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Progenics Pharmaceuticals, Inc.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will evaluate the safety and efficacy of two different dose regimens (12
milligrams [mg] and 24 mg) of IV MOA-728 versus placebo in shortening the time to return of
bowel function in participants receiving opioid analgesia administered via patient-controlled
anesthesia (PCA), and who had undergone repair of large (greater than or equal to [=]10
centimeters) ventral hernias with or without a mesh prosthesis via laparotomy or laparoscopy.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00528970
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Lindsey Mathew
Query!
Address
0
0
Bausch Health Americas, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00528970
Download to PDF